STOCK TITAN

Restart Life Sciences CP (NMLSF) Stock Price, News & Analysis

NMLSF OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
74 87 sessions, November 12, 2025 to November 13, 2026
Largest daily move
+313.7% close of November 13, 2026
1-year change
+13% closing prices, November 12, 2025 to November 13, 2026
1-month change
+15.1% closing prices, October 13, 2026 to November 13, 2026

Company Description

Restart Life Sciences Corp. (OTC Pink: NMLSF) is a Canadian-based life sciences company listed on the Canadian Securities Exchange under the symbol HEAL and on the Frankfurt Stock Exchange under the symbol HN30. According to company disclosures, Restart Life Sciences focuses on the development and creation of consumer health and wellness products with a particular emphasis on brain health, cognitive function, focus, memory, and overall mental wellness.

The company describes itself as operating within the broader health and wellness and life sciences categories, with activities that include food technology, product development, and research initiatives. Restart Life Sciences has introduced and developed several consumer health brands and product platforms that are positioned as functional wellness offerings informed by scientific and research-oriented approaches.

Business focus and product platforms

Restart Life Sciences reports that it has developed brands such as BrainQ™ and BrainBalls™. BrainQ™ is described as a functional product platform formulated with natural ingredients commonly associated with cognitive support, while BrainBalls™ is presented as a nutrient-dense snack designed to support daily brain wellness. The company states that these brands reflect a strategic focus on accessible, science-informed products in the health and wellness category.

BrainQ™ Healthy Cereal is identified as the first product under the BrainQ™ brand. Company information notes that this cereal follows the product line established by BrainBalls™ in cereal form and is intended to be produced in collaboration with a co-packing partner in British Columbia. The cereal is planned in multiple flavor variations and packaging formats, including sachets, travel-sized packs, and wholesale options, with an emphasis on convenience for health-conscious consumers.

BrainBalls™ is described as a functional wellness snack developed through a joint venture with Brain Balls Inc. Restart Life Sciences reports that it has led the reimagining of the BrainBalls™ brand, including product formulation, nutritional development, branding, and packaging design. The snack is characterized as being crafted with clean-label, plant-based ingredients and designed to support mental clarity, cognitive performance, sustained energy, and overall well-being.

Health and wellness strategy

The company states that it remains focused on developing health and wellness products that serve the broader wellness market, with particular emphasis on brain and mental health. This includes products intended to support cognitive function, focus, memory, and individuals with attention-related conditions such as ADHD or related conditions, as described in its public communications.

Restart Life Sciences indicates that it aims to build a portfolio of wellness-focused brands and products that align with a mandate of delivering better-for-you offerings. The company highlights a focus on clean-label and functionally beneficial products for health-conscious consumers and positions its product development efforts at the intersection of nutrition and performance.

Food technology and research initiatives

Restart Life Sciences has announced plans and actions related to food technology and research studies. The company reports that it is allocating capital toward food-related research initiatives intended to support its expanding portfolio of consumer health and wellness products. These research initiatives are described as forming a structured scientific framework to support ingredient assessment, formulation performance analysis, and future product development across its brands.

According to company updates, the anticipated scope of research includes exploratory assessments of ingredient quality, formulation integrity, and functional performance, including stability considerations under varying conditions. The company also notes potential evaluations of sensory attributes, nutrient retention, and ingredient behavior within different formulation matrices, with the goal of informing future optimization efforts.

Restart Life Sciences states that, where appropriate, it may explore preliminary considerations related to bioavailability and the functional potential of select active components, either through primary research partners or in collaboration with additional third-party specialists. The company indicates that outputs from these initiatives may include scientific observations, technical assessments, and advisory recommendations intended to support product development, quality assurance, and continuous improvement.

Acquisition strategy and Holy Crap Foods LOI

In its public disclosures, Restart Life Sciences outlines a growth strategy that includes acquiring and developing profitable brands in the health and wellness, science-informed, better-for-you category. The company has announced a binding letter of intent to acquire 100% of the shares of Holy Crap Foods Inc. from Happy Belly Food Group Inc., subject to customary conditions, due diligence, definitive agreements, and regulatory approvals, including approval by the Canadian Securities Exchange.

Under the terms described in the letter of intent, Restart Life Sciences would, upon closing, acquire the Holy Crap Foods portfolio of brands and a co-packer production facility in British Columbia. The company states that this facility is expected to serve as the production partner for BrainBalls™ and other product lines. Management commentary describes the proposed acquisition as a strategic move intended to accelerate the company’s development roadmap and support vertical integration by controlling more stages of the supply chain.

Holy Crap is described in the company’s news materials as a Canadian health food brand known for high-fibre, plant-based, gluten-free cereals and oatmeal, with a national retail presence across Canada and sales in additional markets. The brand’s mission to promote gut health and overall well-being is noted as aligning with Restart Life Sciences’ mandate of delivering better-for-you products that address various health challenges and support brain and mental health.

Restart Life Sciences indicates that, if completed, the acquisition is expected to add a cash-flow-positive operation and represent a milestone in establishing the company as a revenue-generating entity. The company also notes that it intends to operate Holy Crap as a standalone subsidiary, preserving and strengthening existing operations while seeking to expand into additional markets, new product lines, and complementary wellness products.

Capital raising and financing activities

The company has reported several financing activities intended to support its product development, research, and acquisition plans. These include non-brokered private placements completed in tranches and the exercise of previously issued common share purchase warrants. Restart Life Sciences has also disclosed entering into a loan agreement providing principal funding on agreed terms.

According to company announcements, net proceeds from warrant exercises, private placements, and loan financing are intended to be used to advance the proposed acquisition of Holy Crap Foods Inc., support food-related research initiatives and health food trials, and provide general working capital. These financing activities are presented by the company as supporting its mission and strategic growth plans in the health and wellness sector.

Research orientation and collaborations

Restart Life Sciences emphasizes a research-oriented approach to its functional wellness products. The company states that it is actively seeking collaborations with reputable scientific organizations to validate product efficacy through clinical and functional studies. It indicates that research programs are expected to evolve over time into more advanced and continuous efforts aimed at enhancing product formulation, functional performance, and overall quality.

The company’s communications suggest that this research orientation is intended to provide a scalable and cost-efficient scientific foundation that supports innovation and aligns with its stage of growth and capital resources. This focus on structured research is presented as central to the company’s efforts to strengthen its ability to deliver high-quality, effective health and wellness products.

Corporate context and listing

Restart Life Sciences Corp. identifies itself as a Canadian-based life sciences company listed on the Canadian Securities Exchange. The company’s shares also trade on the OTC Pink market in the United States under the symbol NMLSF and on the Frankfurt Stock Exchange under the symbol HN30. Public communications refer to a mandate of advancing health and wellness products that address brain and mental health, supported by food technology, research, and potential brand acquisitions.

Stock Performance

$0.0633
+313.73%
+0.0480
Last updated: November 13, 2026 at 16:00
+13%
Performance 1 year

Restart Life Sciences CP (NMLSF) closed at $0.0633 on November 13, 2026. Over the past 12 months, the price has gained 13.0%.

See what a $1,000 investment in NMLSF would be worth today

Average down calculator for NMLSF

NMLSF Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

SEC Filings

No SEC filings available for NMLSF.

Financial Highlights

We do not hold any annual figures for Restart Life Sciences CP yet, so there is nothing to show here.

Upcoming Events

DEC
2026
December 2026 Product

AI Platform Launch

Introduction via Holy Crap Foods' AI-enhanced platform scheduled Dec 2026; initial sales planned through DTC channels and Amazon.
DEC
05
December 5, 2026 Financial

Warrants expiration

One-year warrants (including 60,000 finder warrants) expire; exercise price CAD$0.10.
DEC
18
December 18, 2026 Financial

Warrants expiry

6,300,000 transferable +132,000 finder warrants expire; exercise price CDN$0.10; issued Dec 18, 2025.
DEC
22
December 22, 2026 Financial

Loan maturity

CAD$250,000 arm's-length loan at 12% annual interest; 12-month term, payable monthly
Q1
2027
Q1 2027 Product

Canadian E-commerce Launch

Canadian e-commerce launch in Q1 2027 using Gibsons, BC facility for inventory, fulfillment; initial DTC and Amazon sales.
YEAR
2027
2027 Product

Canadian product launch

Planned Canadian launch of BrainBalls snack bites in 2027; sales via Canadian e-commerce and Gibsons warehousing/logistics.
YEAR
2027
2027 Operations

U.S. expansion planning

U.S. expansion is a 2027 priority; company will evaluate online marketplaces, distribution options and timing using Canadian sales data.

Restart Life Sciences CP has 7 upcoming scheduled events. The next event, "AI Platform Launch", is expected in December 2026. 3 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the NMLSF stock price.

Short Interest History

Last 12 Months

Short interest in Restart Life Sciences CP (NMLSF) currently stands at 1 shares.

Days to Cover History

Last 12 Months

Days to cover for Restart Life Sciences CP (NMLSF) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

NMLSF Company Profile & Sector Positioning

Restart Life Sciences CP (NMLSF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing NMLSF often look at related companies in the same sector, including Entheon Biomedical Corp (ENTBF), Doseology Sciences Inc (DOSEF), Avenue Therapeutics Inc (ATXI), ProtoKinetix Inc (PKTX), and Protagenic Therapeutics (PTIX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate NMLSF's relative position within its industry.

Frequently Asked Questions

The current stock price of Restart Life Sciences CP (NMLSF) is $0.0633 as of November 13, 2026.

The market cap of Restart Life Sciences CP (NMLSF) is approximately $4.0M. Learn more about what market capitalization means .